Table 3.

Bioavailability parameters of GRI and CIN (mean±SD, n=4–5)

Drug	Parameters	SUSP	MCT-SNEDDS	LCT-SNEDDS
GRI	Cmax (μg/mL)	0.28±0.08	0.47±0.17*	0.39±0.07
	Tmax (h)	2.80±1.10	4.40±1.67	2.00±0.11
	AUC0–12 h (μg·h/mL)	1.57±0.15	3.07±0.58**	2.62±0.52*
Fr (%)	—	195.54	166.88
CIN	C1max (μg/mL)	0.32±0.09	2.51±0.42**	3.45±0.80**##
	C2max (μg/mL)	0.31±0.07	2.36±0.88**	3.69±0.78**#
	T1max (h)	1.38±0.48	2.50±1.00	7.50±1.00**##
	T2max (h)	8.00±1.63	10.00±2.00	10.50±1.91
	AUC0–48 h (μg·h/mL)	—	68.73±14.76	71.75±6.62
	AUC0–24 h (μg·h/mL)	2.89±1.11	44.20±11.56**	62.51±13.72**#
Fr (%)	—	1,529.41	2,162.98

Notes: *, compared with SUSP, P<0.05; **, compared with SUSP, P<0.01; #, compared with MCT-SNEDDS, P<0.05; ##, compared with MCT-SNEDDS, P<0.01.

Abbreviations: GRI, griseofulvin; CIN, cinnarizine; SUSP, suspension; SNEDDS, self-nanoemulsifying drug delivery system; MCT, medium-chain triglycerides; LCT, long-chain triglycerides; C_max, the maximum blood concentration; T_max, the time to maximum blood concentration; AUC_{0–12 h}, AUC_{0–24 h} and AUC_{0–48 h}, under the plasma concentration-time curves up to 12, 24, and 48 hrs, respectively; F_r, relative oral bioavailability.